Form 4: IN8BIO CEO William Ho Acquires Shares and Warrants in Company
SEC Form 4
IN8BIO's CEO, William Tai-Wei Ho, reports acquisition of common stock and warrants, along with an amendment to existing warrants.
Summary
- On October 4, 2024, William Tai-Wei Ho, the President and CEO of IN8BIO, Inc., acquired 126,582 shares of common stock and related warrants.
- These securities were obtained as part of a purchase of 126,582 Issuer Units at $0.395 per unit, with each unit containing one share of common stock and one Series C warrant.
- Ho also holds 72,999 shares indirectly through a child.
- Additionally, an existing Series A warrant was amended, reducing the exercise price from $1.25 to $0.45 and extending the expiration date to October 4, 2025.
- Following these transactions, Ho directly owns 2,548,094 shares of common stock.
- Ho also indirectly owns 72,999 shares of common stock by child, 73,000 shares of common stock by child, and 36,500 shares of common stock held by a relative of the Reporting Person.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's increased stake in the company is a potentially positive signal, but it's a routine filing.
Positives
- The CEO's purchase of additional shares and warrants could be interpreted as a sign of confidence in the company's future prospects.
- The amendment of the Series A warrant on more favorable terms for the holder could be seen as a positive adjustment.
Industry Context
This filing reflects insider activity, which is closely monitored by investors for signals about management's confidence in the company's prospects. The purchase of shares and warrants by the CEO could be seen as a positive indicator.
Comparison to Industry Standards
- Insider transactions are common in publicly traded companies, and the reporting requirements ensure transparency.
- Comparing the size and frequency of insider transactions at IN8BIO to those of its peers in the biotechnology industry could provide further context.
- Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) saw significant insider activity leading up to major corporate events; however, each company's situation is unique.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive sign.
- The warrant amendment could potentially dilute existing shareholders if the warrants are exercised.
Key Dates
| Date | Description |
|---|---|
| 12/13/2023 | Original grant date of Series A warrants with an exercise price of $1.25 and expiration date of June 13, 2025. |
| 10/04/2024 | Date of transaction: Acquisition of common stock and warrants, and amendment of Series A warrants. |
| 10/04/2025 | New expiration date for the amended Series A warrants. |
| 10/04/2027 | Expiration date for the Series C warrants. |
| 06/13/2025 | Original expiration date of Series A warrants. |
| 10/08/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.